Ascendis Pharma A/S (Ascendis Pharma A/S) Total Liabilities : $1,131.2 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Ascendis Pharma A/S Total Liabilities?

Ascendis Pharma A/S's Total Liabilities for the quarter that ended in Mar. 2024 was $1,131.2 Mil.

Ascendis Pharma A/S's quarterly Total Liabilities increased from Sep. 2023 ($1,010.30 Mil) to Dec. 2023 ($1,059.20 Mil) and increased from Dec. 2023 ($1,059.20 Mil) to Mar. 2024 ($1,131.18 Mil).

Ascendis Pharma A/S's annual Total Liabilities increased from Dec. 2021 ($227.44 Mil) to Dec. 2022 ($875.41 Mil) and increased from Dec. 2022 ($875.41 Mil) to Dec. 2023 ($1,059.20 Mil).

Ascendis Pharma A/S Total Liabilities Historical Data

The historical data trend for Ascendis Pharma A/S's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma A/S Total Liabilities Chart

Ascendis Pharma A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

88.46

171.63

227.44

875.41

1,059.20

Ascendis Pharma A/S Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															855.54	822.30	1,010.30	1,059.20	1,131.18

Ascendis Pharma A/S Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Ascendis Pharma A/S's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	215.206	+	(674.88	+	156.266
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	12.845	+	0)
	=	1,059.2

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	900.313	-	-158.884
	=	1,059.2

Ascendis Pharma A/S's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	868.447	+	(249.595	+	-0.0010000000000936
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	13.136	+	0)
	=	1,131.2

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	872.287	-	-258.89
	=	1,131.2

Ascendis Pharma A/S Total Liabilities Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma A/S's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascendis Pharma A/S (Ascendis Pharma A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma A/S (NAS:ASND) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ASND:Mexico A71:Germany A1SN34:Brazil

Address

Tuborg Boulevard 12, Hellerup, DNK, DK-2900

Website

http://www.ascendispharma.com

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.